Eli Lilly and Co. entered a definitive agreement to acquire Akouos, Inc., a precision genetic medicine company developing a portfolio of adeno-associated viral gene therapies for the treatment of inner ear conditions, for approximately $487 million. The agreement has been approved by the boards of directors of both companies.   “We are honored to work with the talented team at Akouos who are breaking new ground in the science of treating hearing loss,” said Andrew C. Adams, Ph.D., ...